UNSPSC 51141531: Valproic acid

This classification denotes an anticonvulsant agent with the molecular formula C8H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 614OI1Z5WI, chemically known as 4-pentanoic acid, 2-propyl-, (s)- but generally known as valproic acid, which bears US NIH Compound Identifier 3121. European Medicines Agency schedules Valproic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00015MIG.

UNSPSC 51141531 Valproic acid is a Commodity code that state and local governments procure as part of broader pharmaceutical and pharmacy benefit programs, though recent opportunities tagged under this code show little direct activity specific to valproic acid itself. The solicitations in the recent-opportunities block—a naloxone and drug deactivation systems purchase, a Texas HHS therapeutic pharmacy initiative RFI, and a Minnesota multistate cooperative generic pharmaceuticals RFP—indicate that state and local issuing bodies use this code family to classify pharmaceutical procurement across health departments, Medicaid agencies, cooperative purchasing alliances, and county health systems. The actual work involves establishing supply contracts for generic and branded pharmaceuticals, OTC products, and related health commodities through authorized wholesalers, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain authorized distributor relationships, and provide detailed NDC and pricing documentation.

Recent activity spans county health departments (Seminole County, Florida), state Medicaid and HHS agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Department of Administration's MMCAP, serving Minnesota and Oregon). The Seminole County IFB (due July 26, 2023, though posted June 30, 2026 per the record) sought 1,900 units of naloxone and 800 drug deactivation systems annually on a two-year term with optional renewal; the Texas HHS RFI (April 3, 2026) explored direct-to-manufacturer prescription programs outside traditional PBM and GPO channels; and MMCAP's RFP (due March 26, 2026) established multistate contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026, and pricing weighted 75 percent on competitiveness. Geographic concentration appears light in recent records, with activity visible in Florida, Texas, and the Minnesota-Oregon corridor, though the code's pharmaceutical scope suggests broader national state-level Medicaid and employee health benefit purchasing occurs regularly under this and related classifications.